



When Vaccinations are Challenging: From Immune Diseases to Hypersensitivity Reactions

Guest Editor:

Dr. Marco Caminati

Department of Medicine,
University of Verona, Verona
University Hospital, 37134
Verona, Italy

Deadline for manuscript
submissions:

closed (31 May 2021)

Message from the Guest Editor

Dear Colleagues,

Although vaccines have been part of physicians' practice for many years and represent the most successful prevention strategy for communicable diseases, some challenges still characterize their daily use and applicability. In fact, vaccines have been recently proposed as part of the management of some peculiar conditions, such as immune diseases, particularly immunodeficiency, chronic respiratory diseases or bronchiectasis, and autoimmune diseases treated with immunosuppressant drugs. The expected outcomes, as well as their use in specific phenotypes, have not been completely clarified.

Further, risk assessment, prevention, and management of hypersensitivity reactions to vaccines still present some controversial aspects.

This *Vaccines* Special Issue aims at addressing the above-mentioned challenges and unmet needs through reviews and research contributions, including original articles and case series/reports.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com